Diffusion Pharmaceuticals is a drug-discovery and development company, engages in the commercialization of small-molecule therapeutics to treat serious or life-threatening medical conditions by increasing the amount of oxygen to hypoxic tissues. Its products include trans sodium crocetinate and trans bipolar carotenoids molecules, which are used to treat life-threatening conditions, such as trauma, cancer, stroke, cardiovascular diseases, respiratory disorders, peripheral vascular and arterial diseases, and various other conditions.
TypePublic
HQCharlottesville, US
Founded2001
Size (employees)10 (est)
Websitediffusionpharma.com
Diffusion Pharmaceuticals was founded in 2001 and is headquartered in Charlottesville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Diffusion Pharmaceuticals

David Kalergis

David Kalergis

Chairman & Chief Executive Officer
Ben Shealy

Ben Shealy

CFO
David Jones

David Jones

Chief Medical Officer
John Gainer

John Gainer

Chief Scientific Officer
Show more

Diffusion Pharmaceuticals Office Locations

Diffusion Pharmaceuticals has an office in Charlottesville
Charlottesville, US (HQ)
400 1317 Carlton Ave
Show all (1)
Report incorrect company information

Diffusion Pharmaceuticals Financials and Metrics

Diffusion Pharmaceuticals Revenue

USD

Net income (Q2, 2018)

(6.1m)

EBIT (Q2, 2018)

6.4m

Market capitalization (15-Oct-2018)

18.7m

Closing stock price (15-Oct-2018)

0.4

Cash (30-Jun-2018)

12.9m
Diffusion Pharmaceuticals's current market capitalization is $18.7 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

2.5m11.1m6.2m

R&D expense

3.9m7.3m5.1m

Operating expense total

6.4m18.3m11.3m
Quarterly
USDQ2, 2018

General and administrative expense

3.2m

R&D expense

3.2m

Operating expense total

6.4m

Depreciation and amortization

54.7k
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

2.0m1.6m8.9m

Prepaid Expenses

45.9k50.8k769.9k

Current Assets

2.0m1.6m9.7m

PP&E

52.0k79.8k460.7k
Quarterly
USDQ2, 2018

Cash

12.9m

Current Assets

13.7m

PP&E

405.9k

Goodwill

6.9m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(6.7m)(18.0m)(1.4m)

Depreciation and Amortization

8.3k25.3k68.0k

Accounts Payable

647.6k991.6k(1.7m)

Cash From Operating Activities

(5.2m)(10.8m)(12.3m)
Quarterly
USDQ2, 2018

Net Income

(6.1m)

Depreciation and Amortization

54.7k

Cash From Operating Activities

(5.8m)

Cash From Financing Activities

9.9m
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Diffusion Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Diffusion Pharmaceuticals News and Updates

Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment

Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC), r…
Report incorrect company information

Diffusion Pharmaceuticals Company Life and Culture

Report incorrect company information